Ardelyx, Inc.
NASDAQ:ARDX
4.64 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Ardelyx, Inc. |
Symbool | ARDX |
Munteenheid | USD |
Prijs | 4.64 |
Beurswaarde | 1,099,002,560 |
Dividendpercentage | 0% |
52-weken bereik | 4.32 - 10.13 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael G. Raab |
Website | https://www.ardelyx.com |
An error occurred while fetching data.
Over Ardelyx, Inc.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)